Cargando…

ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis

Pancreatic cancer is one of the most lethal cancers and its prognosis is extremely poor. Clarification of molecular mechanisms and identification of prognostic biomarkers are urgently needed. Though we previously found that LGMN was involved in pancreatic carcinoma progression, the upstream regulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Qiang, Ni, Chenming, Lin, Yingying, Sun, Xu, Shen, Zhenhua, Zhang, Minjie, Han, Shuwen, Shi, Jiemin, Mao, Jing, Yang, Zhe, Wang, Weilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711721/
https://www.ncbi.nlm.nih.gov/pubmed/34966781
http://dx.doi.org/10.3389/fmolb.2021.764900
_version_ 1784623419194605568
author Yan, Qiang
Ni, Chenming
Lin, Yingying
Sun, Xu
Shen, Zhenhua
Zhang, Minjie
Han, Shuwen
Shi, Jiemin
Mao, Jing
Yang, Zhe
Wang, Weilin
author_facet Yan, Qiang
Ni, Chenming
Lin, Yingying
Sun, Xu
Shen, Zhenhua
Zhang, Minjie
Han, Shuwen
Shi, Jiemin
Mao, Jing
Yang, Zhe
Wang, Weilin
author_sort Yan, Qiang
collection PubMed
description Pancreatic cancer is one of the most lethal cancers and its prognosis is extremely poor. Clarification of molecular mechanisms and identification of prognostic biomarkers are urgently needed. Though we previously found that LGMN was involved in pancreatic carcinoma progression, the upstream regulation of LGMN remains unknown. We used reliable software to search for the potential transcription factors that may be related with LGMN transcription, we found that ELK1 could be a new regulator of LGMN transcription that binded directly to the LGMN promoter. Moreover, knocking down of ELK1 reduced pancreatic cancer cells proliferation, invasion and survival, while LGMN restored the malignancy of pancreatic cancer in vitro and in vivo. Overexpression of ELK1 further increased cancer cells proliferation, invasion and survival. Clinically, ELK1 and LGMN were positively correlated with clinical stage, degree of differentiation and Lymph node infiltration. ELK1 and LGMN were identified as independent prognostic factors for overall survival. The patients with low expression of ELK1/LGMN survived an average of 29.65 months, whereas those with high expression of ELK1/LGMN survived an average of 16.67 months. In conclusive, our results revealed a new mechanism by which ELK1 promoted the progression of pancreatic cancer via LGMN and conferred poor prognosis.
format Online
Article
Text
id pubmed-8711721
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87117212021-12-28 ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis Yan, Qiang Ni, Chenming Lin, Yingying Sun, Xu Shen, Zhenhua Zhang, Minjie Han, Shuwen Shi, Jiemin Mao, Jing Yang, Zhe Wang, Weilin Front Mol Biosci Molecular Biosciences Pancreatic cancer is one of the most lethal cancers and its prognosis is extremely poor. Clarification of molecular mechanisms and identification of prognostic biomarkers are urgently needed. Though we previously found that LGMN was involved in pancreatic carcinoma progression, the upstream regulation of LGMN remains unknown. We used reliable software to search for the potential transcription factors that may be related with LGMN transcription, we found that ELK1 could be a new regulator of LGMN transcription that binded directly to the LGMN promoter. Moreover, knocking down of ELK1 reduced pancreatic cancer cells proliferation, invasion and survival, while LGMN restored the malignancy of pancreatic cancer in vitro and in vivo. Overexpression of ELK1 further increased cancer cells proliferation, invasion and survival. Clinically, ELK1 and LGMN were positively correlated with clinical stage, degree of differentiation and Lymph node infiltration. ELK1 and LGMN were identified as independent prognostic factors for overall survival. The patients with low expression of ELK1/LGMN survived an average of 29.65 months, whereas those with high expression of ELK1/LGMN survived an average of 16.67 months. In conclusive, our results revealed a new mechanism by which ELK1 promoted the progression of pancreatic cancer via LGMN and conferred poor prognosis. Frontiers Media S.A. 2021-12-13 /pmc/articles/PMC8711721/ /pubmed/34966781 http://dx.doi.org/10.3389/fmolb.2021.764900 Text en Copyright © 2021 Yan, Ni, Lin, Sun, Shen, Zhang, Han, Shi, Mao, Yang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Yan, Qiang
Ni, Chenming
Lin, Yingying
Sun, Xu
Shen, Zhenhua
Zhang, Minjie
Han, Shuwen
Shi, Jiemin
Mao, Jing
Yang, Zhe
Wang, Weilin
ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title_full ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title_fullStr ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title_full_unstemmed ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title_short ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis
title_sort elk1 enhances pancreatic cancer progression via lgmn and correlates with poor prognosis
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711721/
https://www.ncbi.nlm.nih.gov/pubmed/34966781
http://dx.doi.org/10.3389/fmolb.2021.764900
work_keys_str_mv AT yanqiang elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT nichenming elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT linyingying elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT sunxu elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT shenzhenhua elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT zhangminjie elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT hanshuwen elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT shijiemin elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT maojing elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT yangzhe elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis
AT wangweilin elk1enhancespancreaticcancerprogressionvialgmnandcorrelateswithpoorprognosis